Health Canada approves Pithampur-2 unit of Lupin

The Canadian regulator revised establishment licence for Lupin's Indore plant in Pithampur, Unit-2.

Health Canada reviewed the facility and reinstated the Establishment License for the Pithampur Unit-2. The regulator has maintained the compliance rating for the unit. Earlier in November 2017, the US drug regulator, USFDA had issued warning letter to the same unit.

Lupin Limited is a leading global pharma company engaged in branded, generic formulations, biotech products and APls. The company is a leader in Anti-TB space and major player in cardiovascular, diabetes, asthma, CNS, GI, anti-infective and NSAID segment.

At 11:15 hours, the stock of Lupin was quoting Rs. 752.80 per share, up by 16.40 or 2.23 per cent on Monday, when the benchmark index BSE Sensex was at 33,111.64, up by 142.96 points or 0.43 per cent.